Skip to main content

Altamira Therapeutics Ltd. (CYTO)

NASDAQ: CYTO · IEX Real-Time Price · USD
2.09 -0.04 (-1.88%)
Sep 22, 2021 1:22 PM EDT - Market open
Market Cap28.79M
Revenue (ttm)174,475
Net Income (ttm)-8.20M
Shares Out13.64M
EPS (ttm)-1.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,887
Open2.15
Previous Close2.13
Day's Range2.08 - 2.18
52-Week Range0.73 - 6.25
Beta1.33
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CYTO

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in Phase 2 of clinical development for the intranasal treatment of vertigo; Keyzil...

IndustryBiotechnology
IPO DateAug 6, 2014
CEOThomas Meyer
Employees8
Stock ExchangeNASDAQ
Ticker SymbolCYTO
Full Company Profile

Financial Performance

Financial Statements

News

Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program

HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infectio...

1 day ago - Accesswire

Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...

1 week ago - Accesswire

Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results

Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 Enrollment in Phase 2 trial of AM-125 for ...

2 weeks ago - Accesswire

Are These Penny Stocks Worth Watching This Week? 3 For Your List

Which penny stocks are investors watching this week? Here's 3 for your list The post Are These Penny Stocks Worth Watching This Week?

Other symbols:ANYMBIO
1 month ago - PennyStocks

Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)

Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p

1 month ago - Accesswire

Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray

HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection pr...

1 month ago - Accesswire

Auris Medical Announces Launch of New Corporate Website

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and ...

2 months ago - GlobeNewsWire

5 Reddit Penny Stocks to Watch That Are Moving Right Now

Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News an...

Other symbols:ACRXBBDCEIVERB
2 months ago - PennyStocks

Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found t...

2 months ago - Benzinga

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Miti...

Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and ...

2 months ago - GlobeNewsWire

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for Oligo...

Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and i...

2 months ago - GlobeNewsWire

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and ...

2 months ago - GlobeNewsWire

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model ...

Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and ...

3 months ago - GlobeNewsWire

Why Auris Medical Stock Is Moving Today

Auris Medical Holding Ltd (NASDAQ:EARS) shares are trading higher by 12.7% at $4.16 Thursday morning after the company announced the acquisition of RNA therapeutics company Trasir Therapeutics and plans...

3 months ago - Benzinga

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, t...

3 months ago - Benzinga

Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning

Hamilton, Bermuda, June 3, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

3 months ago - GlobeNewsWire

Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

3 months ago - GlobeNewsWire

Auris Medical Holding to Present at LD Micro Invitational XI Conference

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

3 months ago - GlobeNewsWire

Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU

Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

3 months ago - GlobeNewsWire

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

4 months ago - GlobeNewsWire

Auris Medical Falls To Support And Rallies

Since late January, each time shares of Auris Medical Holding Ltd. (NASDAQ:EARS) fell to $2.80 a rally followed.

4 months ago - Benzinga

4 Meme Penny Stocks To Watch As DogeCoin Rises

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other symbols:BTUCKPTEBON
4 months ago - PennyStocks

Auris Medical Stock Is Trading Higher As Bentrio Hit Primary Endpoint Goal In Allergic Rhinitis Study

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional information regarding the results from the clinical trial of its nasal spray, Bentrio, meant for treating people suffering from allergic...

4 months ago - Benzinga

Auris Medical Provides Update on Bentrio Program in Allergy

Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhino...

4 months ago - GlobeNewsWire

Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch

Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rh...

5 months ago - GlobeNewsWire